Selling, General, and Administrative Costs: Cytokinetics, Incorporated vs Arrowhead Pharmaceuticals, Inc.

Biotech SG&A Expenses: A Decade of Change

__timestampArrowhead Pharmaceuticals, Inc.Cytokinetics, Incorporated
Wednesday, January 1, 20142441953617268000
Thursday, January 1, 20153471808919667000
Friday, January 1, 20164099820927823000
Sunday, January 1, 20173202288036468000
Monday, January 1, 20181911005131282000
Tuesday, January 1, 20192655625739610000
Wednesday, January 1, 20205227589052820000
Friday, January 1, 20218098100096803000
Saturday, January 1, 2022124431000177977000
Sunday, January 1, 202390932000173612000
Monday, January 1, 202498761000
Loading chart...

Unlocking the unknown

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Cytokinetics, Incorporated and Arrowhead Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Cytokinetics saw a significant increase in SG&A expenses, peaking in 2022 with a 178% rise compared to 2014. Meanwhile, Arrowhead Pharmaceuticals experienced a more moderate growth, with expenses increasing by approximately 304% over the same period.

Key Insights

  • Cytokinetics' Surge: In 2022, Cytokinetics' SG&A expenses reached their highest, indicating a strategic investment in growth.
  • Arrowhead's Steady Climb: Arrowhead's expenses peaked in 2022, but the growth was more consistent year-over-year.
  • Missing Data: Note that 2024 data for Cytokinetics is unavailable, which may impact trend analysis.

Understanding these trends can provide valuable insights into each company's strategic priorities and operational efficiency.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025